The consensus among Wall Street analysts is currently a . While some analysts maintain a "Buy" rating, recent price targets suggest limited immediate upside. Current Stock Price: ~$14.81 (as of April 27, 2026).
~$14.67, indicating a slight forecasted downside of roughly -1% . Target Range: High of $18.00 and a low of $10.00 . Investment Case: Buy vs. Sell Buy Case (Bullish) Sell/Hold Case (Bearish)
The company expects 2026 to be a "pivotal year" with 2% revenue growth and $650 million in planned cost savings. mylan stock buy or sell
Recent FDA warnings and import alerts regarding manufacturing facilities in India (Indore and Nashik) continue to impact EBITDA estimates.
Mylan (formerly NASDAQ: MYL) no longer exists as an independent stock. In November 2020, Mylan merged with Pfizer’s Upjohn business to form a new company called (NASDAQ: VTRS ). The consensus among Wall Street analysts is currently a
Viatris offers a solid dividend yield of approximately 3.24% , which may appeal to income-focused investors.
Technical analysis indicates a recent "sell signal" from a pivot top point reached in late April 2026. Financial Health & Outlook Sell Buy Case (Bullish) Sell/Hold Case (Bearish) The
Discounted Cash Flow (DCF) models suggest the stock is significantly undervalued, with some estimates placing "fair value" as high as $56.03 .